Marketing-authorisation holder ยท Netherlands
Viiv Healthcare B.V.
85 medicines in 4 countries, as authorisation holder.
Loading your pageโฆ
Loading your pageโฆ
Marketing-authorisation holder ยท Netherlands
85 medicines in 4 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1โ25 of 85
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Apretude | Cabotegravir | EU (EMA) | Authorised | 2023 |
| APRETUDESospensione iniettabile a rilascio prolungato | Cabotegravir | Italy | Authorised | |
| APRETUDE 30 MG COMPRIMIDOS RECUBIERTOS CON PELICULA31,62 mg ยท Comprimido recubierto con pelรญcula | Cabotegravir | Spain | Marketed | 2023 |
| Apretude 30 mg filmomhulde tabletFilmomhulde tablet | Cabotegravir | Netherlands | Authorised | 2023 |
| Apretude 600 mg suspensie voor injectie met verlengde afgifteSuspensie voor injectie | Cabotegravir | Netherlands | Authorised | 2023 |
| APRETUDE 600 MG SUSPENSION INYECTABLE DE LIBERACION PROLONGADA600 mg ยท Suspension inyectable de liberacion prolongada | Cabotegravir | Spain | Marketed | 2023 |
| Celsentri | Maraviroc | EU (EMA) | Authorised | 2007 |
| CELSENTRICompressa rivestita con film | Maraviroc | Italy | Authorised | |
| CELSENTRI 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA150 mg ยท Comprimido recubierto con pelรญcula | Maraviroc | Spain | Marketed | 2007 |
| Celsentri 150 mg, filmomhulde tablettenFilmomhulde tablet | Maraviroc | Netherlands | Authorised | 2007 |
| Celsentri 20 mg/ml, drankDrank | Maraviroc | Netherlands | Authorised | 2017 |
| CELSENTRI 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA300 mg ยท Comprimido recubierto con pelรญcula | Maraviroc | Spain | Marketed | 2007 |
| Celsentri 300 mg, filmomhulde tablettenFilmomhulde tablet | Maraviroc | Netherlands | Authorised | 2007 |
| Combivir | Lamivudine, Zidovudine | EU (EMA) | Authorised | 1998 |
| COMBIVIRCompressa rivestita con film | Lamivudine, Zidovudine | Italy | Authorised | |
| COMBIVIR 150 MG/300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA150 mg + 300 mg ยท Comprimido recubierto con pelรญcula | Lamivudine, Zidovudine | Spain | Marketed | 1998 |
| Combivir, tabletten 150/300 mgFilmomhulde tablet | Lamivudine, Zidovudine | Netherlands | Authorised | 1998 |
| Dovato | Dolutegravir, Lamivudine | EU (EMA) | Authorised | 2019 |
| DOVATOCompressa rivestita con film | Lamivudine, Dolutegravir | Italy | Authorised | |
| DOVATO 50 MG/300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA52.6 mg + 300 mg ยท Comprimido recubierto con pelรญcula | Dolutegravir, Lamivudine | Spain | Marketed | 2019 |
| DOVATO 50 MG/300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA52.6 mg + 300 mg ยท Comprimido recubierto con pelรญcula | Dolutegravir, Lamivudine | Spain | Authorised | 2022 |
| Dovato 50 mg/300 mg filmomhulde tablettenFilmomhulde tablet | Dolutegravir, Lamivudine | Netherlands | Authorised | 2019 |
| Epivir | Lamivudine | EU (EMA) | Authorised | 1996 |
| EPIVIRCompressa rivestita con film | Lamivudine | Italy | Authorised | |
| Epivir 10 mg/ml, drankDrank | Lamivudine | Netherlands | Authorised | 1996 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 29 | 27 | 2 | CompaniesAll medicines |
| Netherlands | 28 | 28 | 0 | CompaniesAll medicines |
| European Union (EMA) | 14 | 13 | 1 | CompaniesAll medicines |
| Italy | 14 | 14 | 0 | CompaniesAll medicines |
Also in the registers of Romania
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la informaciรณn: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sฤnฤtฤศii, Catalogul public naลฃional al preลฃurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.